\-\ Texto\\:\\ \ \(0\)\
\-\ regular\\ prophylactic\\ antibiotics\\ and\\ regular\\ f\\/u\\ with\\ pediatric\\ urology\ \(0\)\
\-\ u\\/s\\:\ \(0\)\
\-\ r\\ kidney\\:\\ demonstrating\\ normal\\ echogenicity\\ and\\ measuring\\ 9\\.5cm\\ \\(upper\\ limit\\ of\\ normal\\ for\\ patient\\ age\\.\\)\\ there\\ is\\ no\\ evidence\\ of\\ hydronephrosis\ \(0\)\
\-\ l\\ kidney\\:\\ elongated\\ measuring\\ 11\\.5cm\\.\\ there\\ is\\ evidence\\ of\\ mild\\ hyperechogenecity\\ of\\ the\\ renal\\ cortex\\.\ \(0\)\
\-\ vcug\\:\\ grade\\ ii\\ reflux\\ on\\ the\\ right\\.\\ grade\\ iv\\ reflux\\ on\\ the\\ left\\ with\\ mild\\ tortuosity\\ of\\ the\\ ureter\\.\\ additionally\\,\\ there\\ are\\ compound\\ calyces\\ of\\ the\\ superior\\ and\\ inferior\\ poles\\ of\\ the\\ left\\ collecting\\ system\\.\\ normal\\ urethra\\ without\\ evidence\\ of\\ posterior\\ urethral\\ valves\\ \\(puv\\)\\.\ \(0\)\
\-\ vesicoureteral\\ reflux\ \(36\)\
\-\ previously\\ healthy\\ 4yo\\ male\\ with\\ a\\ recent\\ history\\ of\\ decreased\\ appetite\\ and\\ approximately\\ 5lb\\ weight\\ loss\\ x\\ 2\\.5wks\\,\\ intermittent\\ vomiting\\ and\\ diarrhea\\ x\\ 2wks\\,\\ and\\ dysuria\\ x\\ 2d\\ presents\\ with\\ fever\\ to\\ 104\\,\\ mild\\ tachycardia\\,\\ and\\ cvat\\ l\\>r\\.\\ initial\\ lab\\ work\\-up\\ reveals\\ increased\\ wbc\\ and\\ the\\ presence\\ of\\ urine\\ nitrites\\ and\\ leukocyte\\ esterase\\.\ \(0\)\
\-\ definition\\:\\ vesioureteral\\ reflux\\ \\(vur\\)\\ describes\\ a\\ process\\ in\\ which\\ there\\ is\\ retrograde\\ passage\\ of\\ urine\\ from\\ the\\ bladder\\ into\\ the\\ upper\\ urinary\\ tract\\.\\ vur\\ can\\ be\\ divided\\ into\\ two\\ categories\\ \\-\\ primary\\ and\\ secondary\\.\\ primary\\ vur\\ is\\ caused\\ by\\ a\\ congenital\\ anomaly\\ of\\ the\\ ureterovesical\\ junction\\ \\(uvj\\)\\ such\\ as\\ a\\ shortened\\ intravesical\\ ureter\\ or\\ an\\ ectopic\\ ureteral\\ opening\\ in\\ the\\ bladder\\ trigone\\.\\ secondary\\ vur\\ is\\ caused\\ by\\ increased\\ intravesical\\ pressure\\ most\\ likely\\ caused\\ by\\ obstruction\\.\\ obstruction\\ could\\ be\\ anatomic\\ \\(such\\ as\\ in\\ posterior\\ urethral\\ valves\\)\\ or\\ functional\\ \\(such\\ as\\ voiding\\ or\\ bladder\\ abnormalities\\)\\ \ \(0\)\
\-\ epidemiology\\:\\ vur\\ is\\ found\\ in\\ 1\\%\\ of\\ newborns\\ and\\ is\\ the\\ most\\ common\\ urologic\\ anomaly\\ found\\ in\\ newborns\\.\\ vur\\ is\\ also\\ present\\ in\\ 30\\-45\\%\\ in\\ young\\ children\\ presenting\\ with\\ a\\ febrile\\ uti\\.\\ factors\\ that\\ increase\\ the\\ risk\\ for\\ vur\\ are\\ race\\ \\(caucasian\\:\\ african\\ american\\ \\=\\ 3\\:1\\)\\,\\ gender\\ \\(f\\:m\\ \\=\\ 2\\:1\\)\\,\\ and\\ age\\ \\(increased\\ risk\\ for\\ younger\\ children\\ and\\ infants\\)\\ \ \(0\)\
\-\ diagnosis\\:\\ the\\ definitive\\ diagnosis\\ can\\ only\\ be\\ made\\ by\\ demonstrating\\ reflux\\ of\\ urine\\ from\\ the\\ bladder\\ to\\ the\\ collecting\\ system\\ via\\ vcug\\ or\\ radionuclide\\ cystogram\\.\\ \ \(0\)\
\-\ clinical\\:\\ vur\\ is\\ characteristically\\ discovered\\ during\\ evaluation\\ for\\ childhood\\ uti\\.\\ appox\\ 50\\%\\ of\\ the\\ cases\\ are\\ bilateral\\ at\\ time\\ of\\ discovery\\.\\ \ \(0\)\
\-\ the\\ international\\ reflux\\ study\\ group\\ has\\ established\\ a\\ standardized\\ grading\\ system\\ to\\ describe\\ the\\ severity\\ of\\ vur\\ based\\ on\\ vcug\\ results\\.\\ \ \(0\)\
\-\ grade\\ i\\:\\ ureteral\\ involvement\\ w\\/o\\ dilation\\ \ \(0\)\
\-\ grade\\ ii\\:\\ ureteral\\ and\\ collecting\\ system\\ involvement\\ w\\/o\\ dilation\\ \ \(0\)\
\-\ grade\\ iii\\.\\ mild\\ ureteral\\ and\\ collecting\\ system\\ dilation\\ w\\/\\ mild\\ \ \(0\)\
\-\ calyceal\\ blunting\\ \ \(1\)\
\-\ grade\\ iv\\:\\ grossly\\ dilated\\ ureter\\ and\\ collecting\\ system\\ w\\/\\ \ \(0\)\
\-\ moderate\\ calyceal\\ blunting\\.\\ \ \(1\)\
\-\ grade\\ v\\:\\ massively\\ dilated\\ and\\ tortuous\\ ureter\\ and\\ collecting\\ \ \(0\)\
\-\ system\\.\\ papillary\\ impression\\ no\\ longer\\ visible\\ in\\ \ \(0\)\
\-\ most\\ calyces\\.\\ \ \(1\)\
\-\ despite\\ a\\ high\\ grade\\ of\\ reflux\\,\\ 60\\%\\ of\\ grades\\ iii\\-v\\ reflux\\ will\\ spontaneously\\ resolve\\ by\\ age\\ 4\\.\\ \ \(0\)\
\-\ treatment\\:\\ initial\\ medical\\ treatment\\ consists\\ of\\ long\\-term\\ prophylactic\\ antibiotic\\ therapy\\ to\\ prevent\\ recurrent\\ urinary\\ tract\\ infections\\ and\\ reduce\\ the\\ incidence\\ of\\ long\\-term\\ complications\\ secondary\\ to\\ repeated\\ infections\\ and\\ longstanding\\ reflux\\.\\ \ \(0\)\
\-\ surgical\\ treatment\\ should\\ be\\ considered\\ when\\ there\\ are\\ repeated\\ infections\\ despite\\ prophylactic\\ antibiotics\\,\\ presence\\ of\\ a\\ ureterocele\\,\\ presence\\ of\\ urinary\\ tract\\ obstruction\\,\\ or\\ if\\ reflux\\ does\\ not\\ resolve\\ past\\ the\\ age\\ of\\ 4\\-5yo\\.\\ currently\\,\\ there\\ are\\ two\\ surgical\\ options\\ \\-\\ open\\ surgical\\ reimplantation\\ of\\ the\\ ureters\\ into\\ the\\ bladder\\ or\\ endoscopic\\ injection\\ of\\ copolymer\\ beneath\\ the\\ uvj\\ mucosa\\.\\ \ \(0\)\
\-\ long\\-term\\ complications\\ include\\ chronic\\ pyelonephritis\\ and\\ renal\\ scarring\\ secondary\\ to\\ recurrent\\ infections\\,\\ hypertension\\,\\ proteinuria\\,\\ decreased\\ renal\\ function\\,\\ and\\ esrd\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ vur\\:\\ 0\\.40881344555026083\ \(0\)\
\-\ reflux\\:\\ 0\\.29008266459140536\ \(0\)\
\-\ grade\\:\\ 0\\.1926780359504018\ \(0\)\
\-\ collecting\\:\\ 0\\.18846859715182898\ \(0\)\
\-\ system\\:\\ 0\\.17886444367208476\ \(0\)\
\-\ of\\:\\ 0\\.17041786631612532\ \(0\)\
\-\ the\\:\\ 0\\.16039609358547838\ \(0\)\
\-\ and\\:\\ 0\\.15226256181580358\ \(0\)\
\-\ ureteral\\:\\ 0\\.13961316691052703\ \(0\)\
\-\ ureter\\:\\ 0\\.1314327513502116\ \(0\)\
\-\ bladder\\:\\ 0\\.12995510849818154\ \(0\)\
\-\ infections\\:\\ 0\\.11828947912846127\ \(0\)\
\-\ vcug\\:\\ 0\\.11358600472067305\ \(0\)\
\-\ prophylactic\\:\\ 0\\.10977730341633626\ \(0\)\
\-\ intravesical\\:\\ 0\\.10236542929286292\ \(0\)\
\-\ mild\\:\\ 0\\.09493261685887192\ \(0\)\
\-\ newborns\\:\\ 0\\.0908474323445024\ \(0\)\
\-\ urine\\:\\ 0\\.08994297305316573\ \(0\)\
\-\ dilation\\:\\ 0\\.08842352451635639\ \(0\)\
\-\ urinary\\:\\ 0\\.08689084677724654\ \(0\)\
\-\ uvj\\:\\ 0\\.08514605514413055\ \(0\)\
\-\ tract\\:\\ 0\\.08417553156659259\ \(0\)\
\-\ age\\:\\ 0\\.08411024996561894\ \(0\)\
\-\ calyceal\\:\\ 0\\.08270772088510255\ \(0\)\
\-\ is\\:\\ 0\\.08255184835233856\ \(0\)\
\-\ caused\\:\\ 0\\.08056814310526497\ \(0\)\
\-\ there\\:\\ 0\\.07996180237499804\ \(0\)\
\-\ secondary\\:\\ 0\\.0794098121539424\ \(0\)\
\-\ blunting\\:\\ 0\\.07844607763167949\ \(0\)\
\-\ calyces\\:\\ 0\\.07794629491466336\ \(0\)\
\-\ uti\\:\\ 0\\.0745680094257027\ \(0\)\
\-\ urethral\\:\\ 0\\.07420665410363073\ \(0\)\
\-\ valves\\:\\ 0\\.07420665410363073\ \(0\)\
\-\ presence\\:\\ 0\\.07219622493783882\ \(0\)\
\-\ by\\:\\ 0\\.07111645244639792\ \(0\)\
\-\ resolve\\:\\ 0\\.07082836861467007\ \(0\)\
\-\ obstruction\\:\\ 0\\.0703809398478966\ \(0\)\
\-\ or\\:\\ 0\\.06991079211366891\ \(0\)\
\-\ repeated\\:\\ 0\\.06956444866335225\ \(0\)\
\-\ in\\:\\ 0\\.0666568031899848\ \(0\)\
\-\ such\\:\\ 0\\.06463421452709182\ \(0\)\
\-\ are\\:\\ 0\\.06354633496099638\ \(0\)\
\-\ renal\\:\\ 0\\.06257208122921071\ \(0\)\
\-\ anomaly\\:\\ 0\\.061305516673791687\ \(0\)\
\-\ despite\\:\\ 0\\.058288586506903\ \(0\)\
\-\ regular\\:\\ 0\\.05783860343315043\ \(0\)\
\-\ iii\\:\\ 0\\.05783860343315043\ \(0\)\
\-\ evidence\\:\\ 0\\.05703291379672785\ \(0\)\
\-\ demonstrating\\:\\ 0\\.05523587374984163\ \(0\)\
\-\ children\\:\\ 0\\.05488738760314721\ \(0\)\
\-\ be\\:\\ 0\\.054347925819700604\ \(0\)\
\-\ increased\\:\\ 0\\.05433510647145831\ \(0\)\
\-\ recurrent\\:\\ 0\\.053712095403509984\ \(0\)\
\-\ hyperechogenecity\\:\\ 0\\.05356342763165105\ \(0\)\
\-\ 4yo\\:\\ 0\\.05356342763165105\ \(0\)\
\-\ 5lb\\:\\ 0\\.05356342763165105\ \(0\)\
\-\ 2wks\\:\\ 0\\.05356342763165105\ \(0\)\
\-\ vesioureteral\\:\\ 0\\.05356342763165105\ \(0\)\
\-\ appox\\:\\ 0\\.05356342763165105\ \(0\)\
\-\ into\\:\\ 0\\.05341373353463254\ \(0\)\
\-\ ii\\:\\ 0\\.052815238245266745\ \(0\)\
\-\ most\\:\\ 0\\.05229312376774548\ \(0\)\
\-\ measuring\\:\\ 0\\.05182227057604399\ \(0\)\
\-\ complications\\:\\ 0\\.051304868768915816\ \(0\)\
\-\ cvat\\:\\ 0\\.05118271464643146\ \(0\)\
\-\ copolymer\\:\\ 0\\.05118271464643146\ \(0\)\
\-\ to\\:\\ 0\\.05023988299252745\ \(0\)\
\-\ puv\\:\\ 0\\.049493571901951125\ \(0\)\
\-\ urologic\\:\\ 0\\.049493571901951125\ \(0\)\
\-\ antibiotics\\:\\ 0\\.04935092217844051\ \(0\)\
\-\ surgical\\:\\ 0\\.04883682764145212\ \(0\)\
\-\ involvement\\:\\ 0\\.04848372496039536\ \(0\)\
\-\ dilated\\:\\ 0\\.04797730958499521\ \(0\)\
\-\ treatment\\:\\ 0\\.04786422024447091\ \(0\)\
\-\ iv\\:\\ 0\\.047863481992406566\ \(0\)\
\-\ risk\\:\\ 0\\.047863481992406566\ \(0\)\
\-\ kidney\\:\\ 0\\.04706084460560479\ \(0\)\
\-\ standardized\\:\\ 0\\.04620775384651355\ \(0\)\
\-\ massively\\:\\ 0\\.04620775384651355\ \(0\)\
\-\ grades\\:\\ 0\\.04620775384651355\ \(0\)\
\-\ 2d\\:\\ 0\\.0454237161722512\ \(0\)\
\-\ nitrites\\:\\ 0\\.0454237161722512\ \(0\)\
\-\ ureterovesical\\:\\ 0\\.0454237161722512\ \(0\)\
\-\ esrd\\:\\ 0\\.0454237161722512\ \(0\)\
\-\ initial\\:\\ 0\\.044937466003311395\ \(0\)\
\-\ cystogram\\:\\ 0\\.04473214593151194\ \(0\)\
\-\ reimplantation\\:\\ 0\\.043553895766734886\ \(0\)\
\-\ found\\:\\ 0\\.043343666391801663\ \(0\)\
\-\ grading\\:\\ 0\\.04304300318703161\ \(0\)\
\-\ tortuosity\\:\\ 0\\.042573027572065276\ \(0\)\
\-\ compound\\:\\ 0\\.042573027572065276\ \(0\)\
\-\ trigone\\:\\ 0\\.042573027572065276\ \(0\)\
\-\ race\\:\\ 0\\.042573027572065276\ \(0\)\
\-\ proteinuria\\:\\ 0\\.042573027572065276\ \(0\)\
\-\ decreased\\:\\ 0\\.04149314591846963\ \(0\)\
\-\ esterase\\:\\ 0\\.04135386044255127\ \(0\)\
\-\ shortened\\:\\ 0\\.04135386044255127\ \(0\)\
\-\ epidemiology\\:\\ 0\\.04135386044255127\ \(0\)\
\-\ beneath\\:\\ 0\\.04135386044255127\ \(0\)\
\-\ primary\\:\\ 0\\.04118980119377269\ \(0\)\
\-\ normal\\:\\ 0\\.04102553705323492\ \(0\)\
\-\ radionuclide\\:\\ 0\\.040997899296952744\ \(0\)\
\-\ discovery\\:\\ 0\\.040997899296952744\ \(0\)\
\-\ voiding\\:\\ 0\\.04066229020181201\ \(0\)\
\-\ international\\:\\ 0\\.04066229020181201\ \(0\)\
\-\ for\\:\\ 0\\.040606513613645895\ \(0\)\
\-\ as\\:\\ 0\\.04036660522980221\ \(0\)\
\-\ characteristically\\:\\ 0\\.04004365954102256\ \(0\)\
\-\ two\\:\\ 0\\.0397805464116457\ \(0\)\
\-\ poles\\:\\ 0\\.03975718513159403\ \(0\)\
\-\ leukocyte\\:\\ 0\\.03975718513159403\ \(0\)\
\-\ categories\\:\\ 0\\.03975718513159403\ \(0\)\
\-\ limit\\:\\ 0\\.03948404003703496\ \(0\)\
\-\ ureterocele\\:\\ 0\\.03948404003703496\ \(0\)\
\-\ gender\\:\\ 0\\.039223038815839745\ \(0\)\
\-\ longstanding\\:\\ 0\\.03897314745733168\ \(0\)\
\-\ 104\\:\\ 0\\.03873345863949385\ \(0\)\
\-\ urethra\\:\\ 0\\.03828157721659242\ \(0\)\
\-\ dysuria\\:\\ 0\\.03828157721659242\ \(0\)\
\-\ describe\\:\\ 0\\.0380680423871137\ \(0\)\
\-\ elongated\\:\\ 0\\.03786200157355768\ \(0\)\
\-\ divided\\:\\ 0\\.03728400471285135\ \(0\)\
\-\ tortuous\\:\\ 0\\.03710332705181536\ \(0\)\
\-\ definition\\:\\ 0\\.03692804356725282\ \(0\)\
\-\ passage\\:\\ 0\\.03692804356725282\ \(0\)\
\-\ urology\\:\\ 0\\.03675784148558499\ \(0\)\
\-\ opening\\:\\ 0\\.036592434472112086\ \(0\)\
\-\ vesicoureteral\\:\\ 0\\.036431559732641436\ \(0\)\
\-\ ureters\\:\\ 0\\.036431559732641436\ \(0\)\
\-\ describes\\:\\ 0\\.036274975501712714\ \(0\)\
\-\ established\\:\\ 0\\.03612245885714575\ \(0\)\
\-\ retrograde\\:\\ 0\\.03582881963819075\ \(0\)\
\-\ upper\\:\\ 0\\.03579683513998844\ \(0\)\
\-\ appetite\\:\\ 0\\.035153183086139815\ \(0\)\
\-\ can\\:\\ 0\\.035152674844988525\ \(0\)\
\-\ younger\\:\\ 0\\.03502690809722341\ \(0\)\
\-\ endoscopic\\:\\ 0\\.03502690809722341\ \(0\)\
\-\ infants\\:\\ 0\\.034903291727631756\ \(0\)\
\-\ pyelonephritis\\:\\ 0\\.034782224331676125\ \(0\)\
\-\ diagnosis\\:\\ 0\\.03472560518603108\ \(0\)\
\-\ posterior\\:\\ 0\\.0346395746081655\ \(0\)\
\-\ scarring\\:\\ 0\\.03454733058203323\ \(0\)\
\-\ febrile\\:\\ 0\\.034433316112665424\ \(0\)\
\-\ tachycardia\\:\\ 0\\.03421172148689249\ \(0\)\
\-\ longer\\:\\ 0\\.034103983405806323\ \(0\)\
\-\ spontaneously\\:\\ 0\\.034103983405806323\ \(0\)\
\-\ reduce\\:\\ 0\\.034103983405806323\ \(0\)\
\-\ childhood\\:\\ 0\\.03389426251649313\ \(0\)\
\-\ consists\\:\\ 0\\.033306616416674505\ \(0\)\
\-\ severity\\:\\ 0\\.03303347132211544\ \(0\)\
\-\ functional\\:\\ 0\\.0328581878375529\ \(0\)\
\-\ with\\:\\ 0\\.03279224825973863\ \(0\)\
\-\ echogenicity\\:\\ 0\\.03268798575588506\ \(0\)\
\-\ impression\\:\\ 0\\.03260469981082924\ \(0\)\
\-\ mucosa\\:\\ 0\\.03228288992457433\ \(0\)\
\-\ grossly\\:\\ 0\\.03212836625189746\ \(0\)\
\-\ group\\:\\ 0\\.0318310085016729\ \(0\)\
\-\ diarrhea\\:\\ 0\\.03168779260462074\ \(0\)\
\-\ antibiotic\\:\\ 0\\.03134432857763511\ \(0\)\
\-\ papillary\\:\\ 0\\.03121237784088345\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.03108332735643989\ \(0\)\
\-\ anatomic\\:\\ 0\\.03108332735643989\ \(0\)\
\-\ prevent\\:\\ 0\\.030712368601976195\ \(0\)\
\-\ definitive\\:\\ 0\\.030593747180093996\ \(0\)\
\-\ discovered\\:\\ 0\\.03053532320871975\ \(0\)\
\-\ on\\:\\ 0\\.03034685247641182\ \(0\)\
\-\ lab\\:\\ 0\\.030251617750381612\ \(0\)\
\-\ african\\:\\ 0\\.030251617750381612\ \(0\)\
\-\ options\\:\\ 0\\.030196485320163377\ \(0\)\
\-\ pediatric\\:\\ 0\\.029980991017721913\ \(0\)\
\-\ caucasian\\:\\ 0\\.02977312645491118\ \(0\)\
\-\ ectopic\\:\\ 0\\.02962191911142632\ \(0\)\
\-\ visible\\:\\ 0\\.029523235096403113\ \(0\)\
\-\ injection\\:\\ 0\\.0291442932534515\ \(0\)\
\-\ incidence\\:\\ 0\\.028831664855663856\ \(0\)\
\-\ american\\:\\ 0\\.028576339382303896\ \(0\)\
\-\ healthy\\:\\ 0\\.028412089212629117\ \(0\)\
\-\ factors\\:\\ 0\\.0283316556167566\ \(0\)\
\-\ open\\:\\ 0\\.027689108178790896\ \(0\)\
\-\ young\\:\\ 0\\.027617936874920816\ \(0\)\
\-\ additionally\\:\\ 0\\.027582672140215522\ \(0\)\
\-\ intermittent\\:\\ 0\\.027375419070914852\ \(0\)\
\-\ via\\:\\ 0\\.027375419070914852\ \(0\)\
\-\ cortex\\:\\ 0\\.02727447284793518\ \(0\)\
\-\ function\\:\\ 0\\.027109992605938972\ \(0\)\
\-\ previously\\:\\ 0\\.026887196637823567\ \(0\)\
\-\ increase\\:\\ 0\\.026887196637823567\ \(0\)\
\-\ junction\\:\\ 0\\.026825063140784155\ \(0\)\
\-\ from\\:\\ 0\\.026604411136024204\ \(0\)\
\-\ presenting\\:\\ 0\\.026237417040965542\ \(0\)\
\-\ results\\:\\ 0\\.026099256297629318\ \(0\)\
\-\ considered\\:\\ 0\\.026099256297629318\ \(0\)\
\-\ made\\:\\ 0\\.025832321209654813\ \(0\)\
\-\ currently\\:\\ 0\\.02572885490807927\ \(0\)\
\-\ hypertension\\:\\ 0\\.025627180321102987\ \(0\)\
\-\ pressure\\:\\ 0\\.025502514052415392\ \(0\)\
\-\ reveals\\:\\ 0\\.025477895313294568\ \(0\)\
\-\ moderate\\:\\ 0\\.02514365122122365\ \(0\)\
\-\ process\\:\\ 0\\.02512048921612522\ \(0\)\
\-\ 60\\:\\ 0\\.02505154641998789\ \(0\)\
\-\ vomiting\\:\\ 0\\.024783596018042604\ \(0\)\
\-\ could\\:\\ 0\\.02436251523255451\ \(0\)\
\-\ abnormalities\\:\\ 0\\.024261799887056675\ \(0\)\
\-\ based\\:\\ 0\\.024261799887056675\ \(0\)\
\-\ congenital\\:\\ 0\\.024065408312612942\ \(0\)\
\-\ wbc\\:\\ 0\\.023673202850208144\ \(0\)\
\-\ 50\\:\\ 0\\.02339103152684863\ \(0\)\
\-\ weight\\:\\ 0\\.02335669481683869\ \(0\)\
\-\ does\\:\\ 0\\.023154787449900672\ \(0\)\
\-\ left\\:\\ 0\\.0228507393039461\ \(0\)\
\-\ inferior\\:\\ 0\\.022786191972055066\ \(0\)\
\-\ fever\\:\\ 0\\.022709035005299357\ \(0\)\
\-\ recent\\:\\ 0\\.022678453890968894\ \(0\)\
\-\ cases\\:\\ 0\\.022527892803681747\ \(0\)\
\-\ study\\:\\ 0\\.02233776339293345\ \(0\)\
\-\ should\\:\\ 0\\.021854518708639987\ \(0\)\
\-\ past\\:\\ 0\\.021801740279759195\ \(0\)\
\-\ no\\:\\ 0\\.021783422201098603\ \(0\)\
\-\ superior\\:\\ 0\\.02177552791176808\ \(0\)\
\-\ will\\:\\ 0\\.02155732459140306\ \(0\)\
\-\ approximately\\:\\ 0\\.02137130394335573\ \(0\)\
\-\ medical\\:\\ 0\\.021286470837625606\ \(0\)\
\-\ clinical\\:\\ 0\\.02122661750915945\ \(0\)\
\-\ during\\:\\ 0\\.021214719712427017\ \(0\)\
\-\ only\\:\\ 0\\.020924850355995332\ \(0\)\
\-\ evaluation\\:\\ 0\\.02042622657265807\ \(0\)\
\-\ loss\\:\\ 0\\.02040547898683547\ \(0\)\
\-\ when\\:\\ 0\\.02023202322545605\ \(0\)\
\-\ likely\\:\\ 0\\.020014898764100304\ \(0\)\
\-\ include\\:\\ 0\\.019928338562342662\ \(0\)\
\-\ chronic\\:\\ 0\\.019880795301136307\ \(0\)\
\-\ time\\:\\ 0\\.0198524530384856\ \(0\)\
\-\ if\\:\\ 0\\.01946056657310247\ \(0\)\
\-\ therapy\\:\\ 0\\.0192441986624212\ \(0\)\
\-\ high\\:\\ 0\\.01903552138083349\ \(0\)\
\-\ common\\:\\ 0\\.018994661364315355\ \(0\)\
\-\ bilateral\\:\\ 0\\.01800065278218803\ \(0\)\
\-\ without\\:\\ 0\\.017666571744486853\ \(0\)\
\-\ present\\:\\ 0\\.01718661217765334\ \(0\)\
\-\ presents\\:\\ 0\\.01611211126182646\ \(0\)\
\-\ also\\:\\ 0\\.01575439119844204\ \(0\)\
\-\ has\\:\\ 0\\.015298863328655134\ \(0\)\
\-\ which\\:\\ 0\\.015229836103931891\ \(0\)\
\-\ male\\:\\ 0\\.01491260287162595\ \(0\)\
\-\ that\\:\\ 0\\.014534930967184391\ \(0\)\
\-\ not\\:\\ 0\\.013222444374063187\ \(0\)\
\-\ an\\:\\ 0\\.012807809043207472\ \(0\)\
\-\ history\\:\\ 0\\.012796463028704231\ \(0\)\
\-\ at\\:\\ 0\\.012650925951887356\ \(0\)\
\-\ right\\:\\ 0\\.011104487203021346\ \(0\)\
\-\ patient\\:\\ 0\\.010893760153328208\ \(0\)\
